학술논문
15057 Safety of baricitinib in patients with atopic dermatitis: Results of pooled data from two phase 3 monotherapy randomized, double-blind, placebo-controlled 16-week trials (BREEZE-AD1 and BREEZE-AD2)
Document Type
Abstract
Author
Source
In Journal of the American Academy of Dermatology December 2020 83(6) Supplement:AB28-AB28
Subject
Language
ISSN
0190-9622